Head-to-head evidence
guselkumab vs SOR102
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT06260163 (registry estimate)
SOR102
Developed by Sorriso Pharmaceuticals
NCT06080048 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · SOR102's landscape